Drug Trial Radar · NCT06477536
Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis
Last checked: Nov 19, 2026Latest source record: Feb 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
33
Planned (sponsor's estimate)
Start
Sep 2, 2024
Primary completion
Dec 30, 2025
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase IIb, long term extension study to evaluate the safety and efficacy of HB0034 in adult subjects with generalized pustular psoriasis (GPP).
Conditions
- Generalized Pustular Psoriasis
Interventions
HB0034Drug
300mg, i.v. Q4W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety endpoints include the proportion of subjects with TEAEsTime frame: 0-24 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital (PKUPH)
Beijing, China · Recruiting
Peking University People's Hospital
Beijing, China · Recruiting
The Second affiliated Hospital zhejiang University School of Medicine
Hangzhou, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.